Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are forms of vitamin B3 that the body turns into NAD+. The biochemical effect is proven: oral doses reliably raise blood NAD+. Clinical benefit in humans is not. Meta-analyses of randomised trials find no improvement in blood sugar, insulin, cholesterol, muscle mass or strength, and only a small diastolic blood-pressure signal so far.
5 of 7 results reported a benefit, from 3 published studies.
3 studies, including a review of trials
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultCardiovascular health — blood pressure, cholesterol, heart function, and circulation.
Also known as: NMN, Nicotinamide mononucleotide, NR, Nicotinamide riboside
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for NMN / NR (NAD+ precursors) in heart health.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysisWang K, et al. · BMC infectious diseases · 2026PMID 41803812 ↗02Energy Drinks as the Legal Cocaine? A Comparative Review of Cardiac Physiopathological and Histopathological PatternsGhamlouch A, et al. · Cardiovascular toxicology · 2025PMID 41266869 ↗03Evaluating the efficacy of ubiquinol in heart failure patients: a systematic review and meta-analysisQazi SU, et al. · Future cardiology · 2024PMID 39049769 ↗04Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysisTzang CC, et al. · Nutrition journal · 2024PMID 39148075 ↗Be the first to share what you noticed with NMN / NR (NAD+ precursors) for heart health. Why counts start empty.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 41901064 2026 | Systematic review | 349 | - | resting diastolic blood pressure (DBP) | -2.15 mmHg (95% CI: -3.68 to -0.61) | Benefit |
| PMID 41901064 2026 | Systematic review | 349 | - | resting systolic blood pressure (SBP) | reported qualitatively | No benefit |
| PMID 41901064 2026 | Systematic review | - | - | resting systolic blood pressure (SBP) in participants aged 60 years and older | -3.94 mmHg (95% CI: -7.06 to -0.82) | Benefit |
| PMID 38871717 2024 | Randomised trial | 90 | 6-months | 6-min walk distance, NR alone vs placebo (6 months) | +17.6 meters (90% CI: +1.8,+∞) | Benefit |
| PMID 38871717 2024 | Randomised trial | 90 | 6-months | 6-min walk distance, NR alone vs placebo, participants taking at least 75% of pills | 31.0 meters | Benefit |
| PMID 29599478 2018 | Randomised trial | - | - | Blood pressure and arterial stiffness (exploratory) | reported qualitatively | Unclear |
| PMID 29599478 2018 | Randomised trial | - | - | NAD+ metabolism in blood | reported qualitatively | Benefit |